Larin Fe 1.5/30

Quick links

Choose a section

Quick links to important sections

Advertisements

Larin Fe 1.5/30

Selected form

Advertisements
Advertisements
Advertisements

Overview of Larin Fe 1.5/30

Quick Facts

Property Description
Active ingredients Norethindrone acetate and Ethinyl estradiol
Form Oral tablet (monophasic)
Pharmacological class Combined hormonal contraceptive (CHC)
Common use Contraception (pregnancy prevention)
Origin Synthetic hormones

What is Larin Fe 1.5/30? Identity and Composition Overview

Larin Fe 1.5/30 is a prescription-only oral tablet medication belonging to the pharmacological class of Combined Hormonal Contraceptives (CHC). The primary purpose of this medication is to provide effective prevention of pregnancy in women who choose this method of contraception. It is a synthetic combination formulation administered orally in a structured 28-day regimen.

Pharmaceutical Class and Form Differentiation

Larin Fe 1.5/30 is categorized as a monophasic Combined Hormonal Contraceptive (CHC) in the oral tablet drug form. This monophasic characteristic signifies that the 21 active tablets maintain a fixed, unchanging concentration of the two hormones throughout the active phase of the cycle. This fixed-dose approach provides a predictable hormonal input, which may be preferred over the shifting levels found in multiphasic contraceptives. Oral contraceptives that combine ethinyl estradiol and norethindrone work mainly by preventing ovulation.

Composition: Synthetic Hormones and Ferrous Fumarate (Fe)

The active components in the yellow tablets are the synthetic progestin Norethindrone acetate and the synthetic estrogen Ethinyl estradiol. A distinguishing feature of Larin Fe 1.5/30 is the "Fe" component, which stands for Ferrous fumarate, an iron compound included in the seven inactive tablets taken during the final week. This component is included to facilitate continuous administration via a 28-day regimen and does not provide a therapeutic contraceptive effect. Other medications share this Norethindrone/Ethinyl Estradiol active combination, but the specific monophasic dosage and integrated iron component define the identity of the Larin Fe 1.5/30 formulation.

Regulatory References

  1. MedlinePlus, NIH
  2. DailyMed, NIH
Advertisements

What side effects are possible with Larin Fe 1.5/30?

Possible side effects and safety information

The safety profile of Larin Fe 1.5/30, a combined hormonal contraceptive, is defined by regulatory documents based on classified frequency and system-organ effects. The most critical safety concerns are categorized as serious adverse reactions, primarily related to the vascular system.

Serious Adverse Reactions

Serious adverse reactions documented in official labeling include Thromboembolic Disorders, such as deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke (cerebrovascular events). The risk of these events is generally considered highest during the first year of use and when the medication is re-initiated after a four-week or longer break. Rarer but serious hepatic risks, such as Hepatic Neoplasia (liver tumors), are also documented, with the risk observed to increase with long-term exposure.

Common Adverse Reactions and System-Organ Classes

The adverse reactions that are most frequently reported (ge 5 percent) include headache, abdominal pain, and breast pain. Other common reactions (1% to 10%) affecting various system-organ classes include nausea/vomiting, mood swing, depression, and weight gain.

System-Organ Class Focus Examples of Documented Reactions
Vascular Disorders Thromboembolism, hypertension
Reproductive System Irregular uterine bleeding, breast tenderness
Nervous System Headache, stroke
Hepatobiliary System Gallbladder disease, hepatic adenoma

Irregular uterine bleeding (spotting or breakthrough bleeding) is an expected event, documented as more frequent during the first three months of use.

Population-Specific Safety Constraints

The medication is contraindicated in women over 35 years of age who smoke due to a significantly elevated risk of serious cardiovascular events. Official safety information also notes that use should generally be delayed until 4 weeks postpartum to address the increased risk of thromboembolism in this period. Furthermore, the product must be discontinued before beginning certain combination drug regimens for Hepatitis C to avoid the risk of liver enzyme elevations.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Larin Fe 1.5/30 is defined by two distinct regulatory considerations: the hormonal agents and the iron supplement component. Overdosage of the active hormonal components, norethindrone acetate and ethinyl estradiol, may lead to documented clinical manifestations such as nausea and withdrawal bleeding in females. These hormonal effects are generally classified in regulatory documents as non-serious and are managed with symptomatic treatment.

However, the primary, severe regulatory concern involves the Ferrous Fumarate (iron) component present in the inactive tablets. Official labeling explicitly cites that accidental overdose of iron-containing products is a leading cause of fatal poisoning, particularly in children younger than six years. This specific risk elevates the severity classification of Larin Fe 1.5/30 overdose to potentially life-threatening.

Due to this serious risk, regulatory guidance mandates immediate action in case of suspected overdose. The official statement advises individuals to get medical help right away or call a poison control center immediately. Management is described as symptomatic and supportive, with continuous observation required in emergency settings to monitor for complications related to iron toxicity.

Advertisements

Therapeutic Uses of Larin Fe 1.5/30

What Larin Fe 1.5/30 Treats: Main Uses and Benefits

The primary therapeutic role of this medication is the management of pregnancy risk for women who choose oral hormonal contraception. This combination is commonly used for contraception, which is the primary therapeutic domain.


This medication is also applied across domains where additional symptomatic support is needed, relevant in situations involving severe dysmenorrhea (cramping and pain), menorrhagia (abnormally heavy blood loss), and moderate acne vulgaris. It helps address symptom clusters that interfere with daily comfort, offering supportive relief during episodes of heightened discomfort.

“The use of this medication supports a sense of stability when symptoms are more noticeable, and may assist with easing symptoms that interfere with daily functioning.”

Establishing a predictable cycle pattern is another key therapeutic benefit, as it supports general well-being during symptomatic phases.


Quick Fact: Symptom Management Focus
Symptom focus: Used for managing symptoms related to heavy menstrual blood loss and severe menstrual pain.
Benefit: Helps ease the overall symptom burden associated with irregular and painful cycles.
Patient context: Relevant for women seeking both contraception and symptomatic relief for gynecologic and dermatologic conditions.

Regulatory References

  1. DailyMed official labeling
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Larin Fe 1.5/30

Larin Fe 1.5/30 is officially indicated for use by women of reproductive potential for pregnancy prevention. It is also allowed for use in females ge 15 years of age who have achieved menarche and seek treatment of moderate acne vulgaris.

The medicine is contraindicated and must not be used by specific populations due to serious health risks identified in regulatory labeling.

Eligibility Status Key Exclusionary Conditions (Contraindications)
Contraindicated Women over age 35 who smoke.
Contraindicated History of or current deep vein thrombosis, pulmonary embolism, cerebral vascular disease, coronary artery disease, or thrombogenic heart conditions.
Contraindicated History of or current breast cancer, other estrogen-dependent cancers, active liver disease, or liver tumors.
Contraindicated Pregnancy, uncontrolled hypertension, diabetes with vascular disease, or migraine headaches with aura.

Conditional Use & Limitations: Use is not recommended for nursing mothers. Initiation must be delayed until at least four weeks postpartum for non-breastfeeding women. Efficacy has not been evaluated in women with a Body Mass Index (BMI) greater than 35 kg/m^2, as stated in official labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This product contains both hormonal components (norethindrone acetate and ethinyl estradiol) and an iron supplement (ferrous fumarate), each having separate interaction profiles.

Pharmacokinetic Interactions (Hormonal Components)

Many medications can decrease the effectiveness of the hormonal components by inducing the CYP3A4 enzyme in the liver and gut, which accelerates the breakdown of ethinyl estradiol and norethindrone. Examples of such medications include certain anticonvulsants (e.g., carbamazepine, phenytoin), antibiotics (e.g., rifampin), and certain HIV/HCV protease inhibitors or non-nucleoside reverse transcriptase inhibitors. This reduction in hormone levels can lead to contraceptive failure or breakthrough bleeding, necessitating the use of an alternative, non-hormonal birth control method. Conversely, ethinyl estradiol may inhibit the metabolism of certain other drugs, such as tizanidine, potentially leading to increased blood levels of those co-administered medications.

Contraindicated Combinations and Restrictions

Use of this medication is contraindicated with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for significant increases in liver enzyme (ALT) elevations. It should also not be given concurrently with certain products like aromatase inhibitors.

Ferrous Fumarate Interactions

The iron component (ferrous fumarate) can interfere with the absorption of certain other oral medications by binding to them in the stomach and intestines. This is a concern for drugs susceptible to chelation by polyvalent cations, such as some tetracycline-class antibiotics. A time-spacing requirement of at least four hours is generally necessary when co-administering with certain bile acid sequestrants like colesevelam to prevent reduced efficacy of Larin Fe 1.5/30.

Advertisements

Mechanism of Action

Central Inhibition of the Ovulatory Pathway

The mechanism of Larin Fe 1.5/30 involves three distinct, complementary actions. The active hormones, Norethindrone and Ethinyl estradiol, act as agonists at the Progesterone (PR) and Estrogen (ER) receptors, primarily within the hypothalamus and pituitary gland. This receptor activation triggers a sustained negative feedback signal that suppresses the release of FSH and LH from the pituitary, thereby interrupting the natural Hypothalamic-Pituitary-Ovarian (HPO) Axis signaling cascade. This systemic suppression physiologically results in anovulation.


Modulation of Peripheral Barrier Tissues

Secondary mechanistic actions occur at peripheral tissues. Progestin agonism at local PR receptors in the cervix alters the function of the secretory glands, leading to the formation of dense, highly viscous cervical mucus. Simultaneously, this hormonal signal transforms the endometrial structure of the uterine lining. The estrogen component supports FSH suppression to influence follicular growth, while the progestin component mediates the LH surge blockade and the peripheral tissue changes. This dual receptor agonism provides sustained physiological modulation of the reproductive cycle.

Advertisements

Dosage and Administration Information

How Larin Fe 1.5/30 Is Used: Administration Guidelines

Larin Fe 1.5/30 is administered through a strict, continuous oral regimen designed around a 28-day cycle. The regimen involves taking one tablet daily at the same time every day to maintain consistent hormonal levels and ensure proper use.

Dosage and Regimen

The 28-day cycle consists of two distinct phases: 21 days of active hormone tablets, followed by 7 days of non-hormonal tablets. The active tablets contain 1.5 mg norethindrone acetate and 30 mcg ethinyl estradiol. The inactive tablets contain 75 mg ferrous fumarate (iron) and are included solely to facilitate the continuous daily dosing habit.

Tablets must be taken in the exact order directed on the blister pack to correctly follow the sequential regimen. Two starting protocols are described: the Day-1 Start (beginning on the first day of menstruation) or the Sunday-Start (beginning on the first Sunday after menstruation starts).

Administration Conditions and Handling Missed Doses

Larin Fe 1.5/30 may be taken with or without meals. If a patient misses one active tablet, standard procedure involves taking the missed tablet as soon as possible and continuing the regular schedule, which may result in taking two tablets on the same day. For more than one missed active tablet, specific procedural steps must be followed, often requiring the use of a non-hormonal back-up method for seven days following the error. The treatment is intended for continuous, long-term administration for as long as contraception is desired.

Advertisements

Recent Clinical Evidence

u1f52c Research Evidence Overview: Studies for Larin Fe 1.5/30


Evidence for Primary Use: Pregnancy Prevention (Contraception)

Research examining pregnancy prevention with this combination formulation involves randomized controlled trials (RCTs) and long-term observational analysis. These studies monitored outcomes related to systemic or functional imbalance, specifically measuring rates of pregnancy and documenting patterns in menstrual cycle consistency. The findings documented in these core studies were observed to align with patterns found in research of other low-dose combination contraceptives reviewed by regulators.

Evidence for Symptom Management: Acne and Menstrual Symptoms

This formulation was studied for its application in managing moderate acne vulgaris. Clinical research monitored outcomes by quantifying the number of acne lesions and evaluating overall severity in specific populations, including adolescent females. Evidence is limited in that measurable changes may only be monitored after six months of continuous therapy.

The formulation was evaluated in the context of severe menstrual pain (dysmenorrhea) and heavy menstrual blood loss (menorrhagia). The evidence for these supportive uses is largely drawn from systematic reviews and randomized controlled trials of the entire therapeutic class. Research monitored outcomes related to physical discomfort, daily functioning, and blood loss volume over several cycles.

Research Gaps and Uncertainty

Research examined continuous use for about 12 to 13 menstrual cycles in pivotal trials, but long-term effects are not fully established. Data for certain groups remain insufficient, as evidence suggests that specific data is limited for women with a higher body mass index (BMI), typically defined as over 35 kg/m^2. Furthermore, many supportive uses rely on evidence extrapolated from the wider contraceptive class, meaning comparative data specific to this 1.5 mg/30 mcg dosage is often lacking.

Key Studies & References

  1. Norethindrone Acetate and Ethinyl Estradiol and Ferrous Fumarate tablets (Official FDA/DailyMed Label)
  2. Ethinyl Estradiol and Norethindrone (Oral Route) - MedlinePlus Drug Information
  3. ACOG Practice Bulletin No. 198: Use of Hormonal Contraception in Adolescents and Women
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Larin Fe 1.5/30 (FAQ)

Q: Does Larin Fe 1.5/30 help treat acne?

According to official product information, this medication is indicated for the treatment of moderate acne vulgaris in certain females. This indication applies to those who are at least 15 years old, have started having menstrual periods, and have chosen to use an oral contraceptive for birth control.

Q: How long does Larin Fe 1.5/30 take to become fully effective?

Regulatory documents state that if use is started on a day other than the first day of your menstrual cycle, you should use a back-up non-hormonal contraceptive method for the first 7 days. This backup method should be used for protection during the initial period of use until hormonal levels are established.

Q: Can I drink alcohol while taking Larin Fe 1.5/30?

Official drug labels for this class of medication generally do not list a specific interaction with alcohol. However, it is essential to take the tablet at the same time every day, as missing a tablet for any reason may compromise the medication's effectiveness.

Q: What makes the active tablets different from the iron tablets?

The tablets in the 28-day pack serve two different purposes. The active yellow tablets contain the synthetic hormones (norethindrone acetate and ethinyl estradiol) that prevent pregnancy. The brown tablets contain only ferrous fumarate (iron) and are non-hormonal; they are included solely to help maintain the habit of taking one pill every day.

Q: Will Larin Fe 1.5/30 protect me from sexually transmitted diseases (STDs)?

No. According to patient counseling information, this product does not protect against HIV infection (AIDS) and other sexually transmitted infections. Its use is solely for pregnancy prevention and, where indicated, acne treatment.

Q: Can I still get pregnant if I get breakthrough bleeding or spotting?

Breakthrough bleeding or spotting is a documented and expected event, particularly during the first three months of using this contraceptive. If bleeding is persistent, recurrent, or unusually heavy, the label recommends that non-hormonal causes like malignancy or pregnancy be considered.

Advertisements

How should Larin Fe 1.5/30 be stored and disposed of?

How to Store and Dispose of Larin Fe 1.5/30

The following storage and disposal requirements are based on official government regulatory documents.


Storage Requirements

Larin Fe 1.5/30 must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). Temporary temperature excursions are permitted between 15 C and 30 C.

The medication must be kept in the container it came in and the container should be kept tightly closed. Storage areas must protect the tablets from excess moisture, heat, and freezing. This product must always be kept out of the reach of children and pets.


️ Disposal Instructions

Dispose of any unused or expired Larin Fe 1.5/30 after the expiration date. Official guidelines prohibit discarding the tablets by flushing them down a toilet or pouring them down a drain.

Proper disposal requires following local instructions, such as using a drug take-back program or consulting with a healthcare professional regarding appropriate disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Larin Fe 1.5/30 found in:

A-Z Index: